EC5026 clinical trials
How each study uses EC5026 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the EC5026 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- EC5026 oral tablet
- 5
Studies by the year they started
6 studies that test it; most in 2026 (2)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2021 | 1 |
| 2023 | 1 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
EicOsis Human Health Inc. (6)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test EC5026.
- Dec 2026Safety, Tolerability and Exploratory Efficacy of EC5026 in Parkinson's Disease (STEP Study)Phase 1/2 · EicOsis Human Health Inc.
- Dec 2026Renal Impairment Study for Oral EC5026Phase 1 · EicOsis Human Health Inc.
Studies
Open first, then newest update. How each study uses EC5026 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Novel Soluble Epoxide Hydrolase Inhibitor for Neuropathic Pain in Patients With Spinal Cord InjuryRecruitingPhase 1EicOsis Human Health Inc.NCT06438471Written as EC5026 oral tablet
- Renal Impairment Study for Oral EC5026RecruitingPhase 1EicOsis Human Health Inc.NCT07694544Written as EC5026 oral tablet
- Safety, Tolerability and Exploratory Efficacy of EC5026 in Parkinson's Disease (STEP Study)RecruitingPhase 1/2EicOsis Human Health Inc.NCT07142044Written as EC5026 oral tablet
- Safety, Tolerability, and Pharmacokinetics of Multiple Doses of Oral EC5026 in Healthy SubjectsCompletedPhase 1EicOsis Human Health Inc.NCT06089837Written as EC5026 oral tablet
- Safety, Tolerability, Pharmacokinetics and Food Effects of Oral EC5026 in Healthy SubjectsCompletedPhase 1EicOsis Human Health Inc.NCT04908995Written as EC5026 oral tablet
- Safety, Tolerability, and Pharmacokinetics of Oral EC5026 in Healthy SubjectsCompletedPhase 1EicOsis Human Health Inc.NCT04228302Written as EC5026 oral capsule
Codes
What other systems call EC5026 · ClinicalTrials.gg INT001619
- MeSH (NLM) C000717068EC5026One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000717068 | EC5026 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.